|
|
|
| Advances in the Development of Liver Organoids |
| Jing Sijia1,2,3#, Zheng Huilin1,2,3*, Zhang Lei1,2,3#* |
1(School of Biological and Chemical Engineering, Zhejiang University of Science and Technology, Hangzhou 310023, China)
2(Zhejiang Provincial Collaborative Innovation Center of Agricultural Biological Resources Biochemical Manufacturing, Hangzhou 310023, China)
3(Zhejiang Provincial Key Laboratory of Chemistry and Biological Processing Technology of Farm Products, Hangzhou 310023, China) |
|
|
|
|
Abstract The main purpose of liver pathology research is to study the pathogenesis and drug development of fatty liver, hepatitis, liver fibrosis and liver cancer. At the same time, liver disease is complicated and difficult to treat and shows a tendency of disease progression. The development from fatty liver to cirrhosis and then to liver cancer requires a whole-process research model. At present, liver diseases are mainly studied through two-dimensional cell culture in vitro and animal models in vivo, but neither can fully reveal the pathogenesis of liver diseases and the effect of drug treatment. The development of liver organoids through three-dimensional culture technology makes the further study of liver diseases possible. In this paper, the advances in the field of liver organoids and their applications in biomedicine were reviewed. The key technologies including the selection of seed cells and the construction method of liver organoids were summarized, and their practical applications in building disease models, screening drugs and the detection of hepatotoxicity were introduced, which proved the importance of liver organoids.
|
|
Received: 08 June 2020
|
|
|
| About author:: Member, Chinese Society of Biomedical Engineering |
|
|
|
[1] Ishibashi H, Nakamura M, Komori A, et al. Liver archi-tecture, cell function, and disease [J]. Semin Immunopathol, 2009, 31(3): 399-409.
[2] Malarkey DE, Johnson K, Ryan L, et al. New insights into functional aspects of liver morphology [J]. Toxicologic Pathology, 2005, 33(1): 27-34.
[3] Pimpin L, Cortez-Pinto H, Negro F, et al. Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies [J]. Hepatology, 2018, 69(3): 718-735.
[4] Wang Fusheng, Fan Jiangao, Zhang Zheng, et al. The global burden of liver disease: The major impact of China [J]. Hepatology, 2014, 60(6): 2099-2108.
[5] Byass P. The global burden of liver disease: A challenge for methods and for public health [J]. BMC Medicine, 2014, 12(1): 159.
[6] Baxter M, Withey S, Harrison S, et al. Phenotypic and functional analyses show stem cell-derived hepatocyte-likecells better mimic fetal rather than adult hepatocytes [J]. Hepatology, 2015, 62(3): 581-589.
[7] Duval K, Grover H, Han LH, et al. Modeling physiological events in 2D vs. 3D cell culture [J]. Physiology, 2017, 32(4): 266-277.
[8] Wang Wei, Hu Zhenhua, Huang Yu, et al. Pretreatment with gemcitabine/5-fluorouracil enhances the cytotoxicity of Trastuzumab to HER2-negative human gallbladder cancer cells in vitro and in vivo [J]. Bio Res Int, 2019, 2019: 9205851.
[9] Garber K. From human to mouse and back: 'Tumorgraft' models surge in popularity [J]. Natl Cancer Inst, 2009, 101(1): 6-8.
[10] Aparicio S, Hidalgo M, Kung AL. Examining the utility of patient-derived xenograft mouse models [J]. Nat Rev Cancer, 2015, 15(5): 311-316.
[11] Rubio-Viqueira B, Jimeno A, Cusatis G, et al. An in vivo platform for translational drug development in pancreatic cancer [J]. Clinical Cancer Research, 2006, 12(15): 4652-4661.
[12] Ben-David U, Ha G, Tseng YY, et al. Patient-derived xenografts undergo mouse-specific tumor evolution [J]. Nat Genet, 2017, 49(11): 1567-1575.
[13] Jung J, Seol HS, Chang S. The Generation and Application of Patient-Derived Xenograft Model for Cancer Research [J]. Cancer Res Treat, 2018, 50(1): 1-10.
[14] Byrne AT, Alférez DG, Amant F, et al. Interrogating open issues in cancer precision medicine with patient-derived xenografts [J]. Nat Rev Cancer, 2017, 17(4): 254-268.
[15] Akbari S, Arslan N, Senturk S, et al. Next-generation liver medicine using organoid models [J]. Front Cell Dev Biol, 2019, 7: 345.
[16] Deng Jiu, Zhang Xiuli, Chen Zongzheng, et al. A cell lines derived microfluidic liver model for investigation of hepatotoxicity induced by drug-drug interaction [J]. Biomicrofluidics, 2019, 13(2): 024101.
[17] Lu Yanhua, Zhang Guoliang, Shen Chong, et al. A novel 3D liver organoid system for elucidation of hep vatic glucose metabolism [J]. Biotechnol Bioeng, 2012, 109 (2): 595-604.
[18] Astashkina A, Grainger DW. Critical analysis of 3-D organoid in vitro cell culture models for high-throughput drug candidate toxicity assessments [J]. Adv Drug Deliv Rev, 2014, 69-70: 1-18.
[19] Mizumoto H, Ishihara K, Nakazawa K, et al. A new culture technique for hepatocyte organoid formation and long-term maintenance of liver-specific functions [J]. Tissue Eng Part C Methods, 2008, 14(2): 167-175.
[20] Mitaka T, Sato F, Mizuguchi T, et al. Reconstruction of hepatic organoid by rat small hepatocytes and hepatic nonparenchymal cells [J]. Hepatology, 1999, 29(1): 111-125.
[21] Michalopoulos GK, Bowen WC, Mule K, et al. Histological organization in hepatocyte organoid cultures [J]. American Journal of Pathology, 2001, 159 (5): 1877-1887.
[22] Michalopoulos GK, Bowen WC, Mule K, et al. Hepatocytes undergo phenotypic transformation to biliary epithelium in organoid cultures [J]. Hepatology, 2002, 36(2): 278-283.
[23] Harada K, Mitaka T, Miyamoto S, et al. Rapid formation of hepatic organoid in collagen sponge by rat small hepatocytes and hepatic nonparenchymal cells [J]. Journal of Hepatology, 2003, 39(5): 716-723.
[24] Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors [J]. Cell, 2007, 131: 861-872.
[25] Baptista PM, Siddiqui MM, Lozier G, et al. The use of whole organ decellularization for the generation of a vascularized liver organoid [J]. Hepatology, 2011, 53: 604-617.
[26] Takebe T, Sekine K, Enomura M, et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant [J]. Nature, 2013, 499(7459): 481-484.
[27] Huch M, Dorrell C, Boj SF, et al. In vitro expansion of single Lgr5+ liver stem cells induced by WNT-driven regeneration [J]. Nature, 2013, 494(7436): 247-250.
[28] Ma Xuanyi, Qu Xin, Zhu Wei, et al. Deterministically patterned biomimetic human iPSC-derived hepatic model via rapid 3D bioprinting [J]. Proc Natl Acad Sci, 2016, 113: 2206-2211.
[29] Broutier L, Mastrogiovanni G, Verstegen MM, et al. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening [J]. Nature Medicine, 2017, 23(12): 1424-1435.
[30] Koike H, Iwasawa K, Ouchi R, et al. Modelling human hepato-biliary-pancreatic organogenesis from the foregut-midgut boundary [J]. Nature, 2019, 574(7776): 112-116.
[31] Prior N, Inacio P, Huch M. Liver organoids: From basic research to therapeutic applications [J]. Gut, 2019, 68(12): 2228-2237.
[32] Koike H, Iwasawa K, Ouchi R, et al. Modelling human hepato-biliary-pancreatic organogenesis from the foregut-midgut boundary [J]. Nature, 2019, 574(7776): 112-116.
[33] Mun SJ, Ryu JS, Lee MO, et al. Generation of expandable human pluripotent stem cell-derived hepatocyte-like liver organoids [J]. Hepatology, 2019, 71: 970-985.
[34] Ng SS, Saeb-Parsy K, Blackford S, et al. Human iPSC derived progenitors bioengineered into liver organoids using an inverted colloidal crystal poly (ethylene glycol) scaffold [J]. Biomaterials, 2018, 182, 299-311.
[35] Zhang Ranran, Koido M, Tadokoro T, et al. Human iPSC-derived posterior gut progenitors are expandable and capable of forming gut and liver organoids [J]. Stem Cell Reports, 2018, 10(3): 780-793.
[36] Wang Yaping, Wang Hui, Deng Pengwei, et al. In situ differentiation and generation of functional liver organoids from human iPSCs in a 3D perfusable chip system [J]. Lab on a Chip, 2018, 18(23): 3606-3616.
[37] Guan Yuan, Xu Dan, Garfin PM, et al. Human hepatic organoids for the analysis of human genetic diseases [J]. JCI Insight, 2017, 2(17): e94954.
[38] Sgodda M, Dai Z, Zweigerdt R, et al. A scalable approach for the generation of human pluripotent stem cell-derived hepatic organoids with sensitive hepatotoxicity features [J]. Stem Cells and Development, 2017, 26(20), 1490-1504.
[39] Rashid ST, Corbineau S, Hannan N, et al. Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells [J]. Clin Invest, 2010, 120(9): 3127-3136.
[40] Li Jing, Xing Feiyue, Chen Feng, et al. Functional 3D human liver bud assembled from MSC-derived multiple liver cell lineages [J]. Cell Transplantation, 2018, 28(5): 510-521.
[41] Song Wei, Lu YC, Frankel AS, et al. Engraftment of human induced pluripotent stem cell-derived hepatocytes in immunocompetent mice via 3D co-aggregation and encapsulation [J]. Scientific Reports, 2015, 5(1): 16884.
[42] Nagamoto Y, Tashiro K, Takayama K, et al. The promotion of hepatic maturation of human pluripotent stem cells in 3D co-culture using type I collagen and Swiss 3T3 cell sheets [J]. Biomaterials, 2012, 33(18): 4526-4534.
[43] Furuya K, Zheng Yunwen, Sako D, et al. Enhanced hepatic differentiation in the subpopulation of human amniotic stem cells under 3D multicellular microenvironment [J]. World J Stem Cells, 2019, 11(9): 705-721.
[44] Hu Huili, Gehart H, Artegiani B, et al. Long-term expansion of functional mouse and human hepatocytes as 3D organoids [J]. Cell, 2018, 175(6): 1591-1606.
[45] Gómez-Mariano G, Matamala N, Martínez S, et al. Liver organoids reproduce alpha 1 antitrypsin deficiency related liver disease [J]. Hepatology International, 2019, 14(1): 127-137.
[46] Garnier D, Li Ruoya, Delbos F, et al. Expansion of human primary hepatocytes in vitro through their amplification as liver progenitors in a 3D organoid system [J]. Scientific Reports, 2018, 8: 8222.
[47] Peng Wengchuang, Logan CY, Fish M, et al. Inflammatory cytokine TNFa promotes the long-term expansion of primary hepatocytes in 3D culture[J]. Cell, 2018,175(6):1607-1619.
[48] Broutier L, Andersson-Rolf A, Hindley CJ, et al. Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation [J]. Nature Protocols, 2016, 11(9): 1724-1743.
[49] Sun Sujie, Guo Hua, Wang Jianshe, et al. Hepatotoxicity of perfluorooctanoic acid and two emerging alternatives based on a 3D spheroid model [J]. Environmental Pollution, 2019, 246: 955-962.
[50] Bell CC, Hendriks DF, Moro SM, et al. Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease [J]. Sci Rep, 2016, 6: 25187.
[51] Vyas D, Baptista PM, Brovold M, et al. Self-assembled liver organoids recapitulate hepatobiliary organogenesis in vitro [J]. Hepatology, 2017, 67(2): 750-761.
[52] Saheli M, Sepantafar M, Pournasr B, et al. Three-dimensional liver-derived extracellular matrix hydrogel promotes liver organoids function [J]. Cellular Biochemistry, 2018, 119(6): 4320-4333.
[53] Nie Yunzhong, Zheng Yunwen, Ogawa M, et al. Human liver organoids generated with single donor-derived multiple cells rescue mice from acute liver failure [J]. Stem Cell Research & Therapy, 2018, 9(1): 5-16.
[54] Takebe T, Sekine K, Kimura M, et al. Massive and reproducible production of liver buds entirely from human pluripotent stem cells [J]. Cell Reports, 2017, 21(10): 2661-2670.
[55] Takebe T, Zhang Ranran, Koike H, et al. Generation of a vascularized and functional human liver from an iPSC-derived organ bud transplant [J]. Nature Protocols, 2014, 9(2): 396-409.
[56] Asai A, Aihara E, Watson C, et al. Paracrine signals regulate human liver organoid maturation from induced pluripotent stem cells [J]. Development, 2017, 144(6): 1056-1064.
[57] Wang Luyuan, Liu Liping, Ge Jianyun, et al. A multiple-cell microenvironment in a three-dimensional system enhances direct cellular reprogramming into hepatic organoids [J]. Transplantation Proceedings, 2018, 50(9): 2864-2867.
[58] Lu Yanhua, Zhang Guoliang, Shen Chong, et al. A novel 3D liver organoid system for elucidation of hepatic glucose metabolism [J]. Biotechnol Bioeng, 2012, 109 (2): 595-604.
[59] Devarasetty M, Wang E, Soker S, et al. Mesenchymal stem cells support growth and organization of host-liver colorectal-tumor organoids and possibly resistance to chemotherapy [J]. Biofabrication, 2017, 9(2): 021002.
[60] Leung M, Kievit FM, Florczyk SJ, et al. Chitosan-alginate scaffold culture system for hepatocellular carcinoma increases malignancy and drug resistance. Pharm [J]. Res, 2010, 27(9): 1939-1948.
[61] Mersch-Sundermann V, Knasmuller S, Wu Xinjiang, et al. Use of a human-derived liver cell line for the detection of cytoprotective, antigenotoxic and cogenotoxic agents [J]. Toxicology, 2004, 198(1-3): 329-340.
[62] Cao Wanlu, Liu Jiaye, Wang Ling, et al. Modeling liver cancer and therapy responsiveness using organoids derived from primary mouse liver tumors [J]. Carcinogenesis, 2019, 40(1): 145-154.
[63] Mitaka T. The current status of primary hepatocyte culture [J]. Int. J. Exp Pathol, 1998, 79(6): 393-409.
[64] Zheng Huilin, Zou Weibin, Shen Jiaying, et al. Opposite effects of coinjection and distant injection of mesenchymal stem cells on breast tumor cell growth [J]. Stem Cells Translational Medicine, 2016, 5(9): 1216-1228.
[65] Unadkat HV, Groen N, Doorn J, et al. High content imaging in the screening of biomaterial-induced MSC behavior [J]. Biomaterials, 2013, 34(5): 1498-1505.
[66] Pang Yuan, Sutoko S, Wang Zitong, et al. Organization of liver organoids using Raschig ring-like micro-scaffolds and triple co-culture: Toward modular assembly-based scalable liver tissue engineering [J]. Medical Engineering and Physics, 2019, 13: 11.
[67] Gessner RC, Hanson AD, Feingold S, et al. Functional ultrasound imaging for assessment of extracellular matrix scaffolds used for liver organoid formation [J]. Biomaterials, 2013, 34(37): 9341-9351.
[68] Moscato S, Ronca F, Campani D, et al. Poly (vinyl alcohol)/gelatin hydrogels cultured with hepg2 cells as a 3D model of hepatocellular carcinoma: A morphological study [J]. Funct Biomater, 2015, 6(1): 16-32.
[69] Leung M, Kievit FM, Florczyk SJ, et al. Chitosan-alginate scaffold culture system for hepatocellular carcinoma increases malignancy and drug resistance [J]. Pharm Res, 2010, 27(9): 1939-1948.
[70] Yip D, Cho CH. A multicellular 3d heterospheroid model of liver tumor and stromal cells in collagen gel for anti-cancer drug testing. Biochem. Biophys [J]. Res Commun, 2013, 433(3): 327-332.
[71] Bokhari M, Carnachan RJ, Cameron NR, et al. Culture of HepG2 liver cells on three dimensional polystyrene scaffolds enhances cell structure and function during toxicological challenge [J]. Anat, 2007, 211(4): 567-576.
[72] Skardal A, Smith L, Bharadwaj S, et al. Tissue specific synthetic ECM hydrogels for 3-D in vitro maintenance of hepatocyte function [J]. Biomaterials, 2012, 33(18): 4565-4575.
[73] Wu Min, Yang Zehong, Liu Yanfei, et al. The 3-D culture and in vivo growth of the human hepatocellular carcinoma cell line HepG2 in a self-assembling peptide nanofiber scaffold [J]. Nanomater, 2010, 2010: 1-7.
[74] Fan Jinyong, Shang Yi, Yuan Yingjin, et al. Preparation and characterization of chitosan/galactosylated hyaluronic acid scaffolds for primary hepatocytes culture [J]. Mater Sci Mater Med, 2010, 21(1): 319-327.
[75] Feng Zhangqi, Chu Xuehui, Huang Ningping, et al. The effect of nanofibrous galactosylated chitosan scaffolds on the formation of rat primary hepatocyte aggregates and the maintenance of liver function [J]. Biomaterials, 2009, 30(14): 2753-2763.
[76] Williams CM, Mehta G, Peyton SR, et al. Autocrine-controlled formation and function of tissue-like aggregates by primary hepatocytes in micropatterned hydrogel arrays [J]. Tissue Eng Part A, 2011, 17(7-8): 1055-1068.
[77] Wang Shuyong, Wang Xuan, Tan Zuolong, et al. Human ESC-derived expandable hepatic organoids enable therapeutic liver repopulation and pathophysiological modeling of alcoholic liver injury [J]. Cell Research, 2019, 29(12): 1009-1026.
[78] Saheli M, Sepantafar M, Pournasr B, et al. Three-dimensional liver-derived extracellular matrix hydrogel promotes liver organoids function [J]. Cellular Biochemistry, 2018, 119(6), 4320-4333.
[79] Gieseck RL 3rd, Hannan NR, Bort R, et al. Maturation of induced pluripotent stem cell derived hepatocytes by 3D-culture [J]. PLoS ONE, 2014, 9(1): e86372.
[80] Lee HJ, Son M J, Ahn J, et al. Elasticity-based development of functionally enhanced multicellular 3D liver encapsulated in hybrid hydrogel [J]. Acta Biomaterialia, 2017, 64: 67-79.
[81] Skardal A, Smith L, Bharadwaj S, et al. Tissue specific synthetic ECM hydrogels for 3-D in vitro maintenance of hepatocyte function [J]. Biomaterials, 2012, 33(18): 4565-4575.
[82] Takebe T, Sekine K, Enomura M, et al. Vascularized and functional human liver from an iPSCC-derived organ bud transplant [J]. Nature, 2013, 499(7459): 481-484.
[83] Broutier L, Andersson-Rolf A, Hindley CJ, et al. Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation [J]. Nat Protoc, 2016, 11: 1724-1743.
[84] Massai D, Isu G, Madeddu D, et al. A Versatile bioreactor for dynamic suspension cell culture. Application to the culture of cancer cell spheroids [J]. PLoS ONE, 2016, 11(5): e0154610.
[85] Schneeberger K, Sánchez-Romero N, Ye S, et al. Large-scale production of LGR5-positive bipotential human liver stem cells [J]. Hepatology, 2020, 72(1): 257-270.
[86] Huch M, Gehart H, van Boxtel R, et al. Long-term culture of genome-stable bipotent stem cells from adult human liver [J]. Cell, 2015, 160(1-2): 299-312.
[87] Guan Yuan, Chen Xinyu, Wu Manhong, et al. The phosphatidylethanolamine biosynthesis pathway provides a new target for cancer chemotherapy [J], Hepatology, 2020, 72(4): 746-760.
[88] Leite SB, Roosens T, El Taghdouini A, et al. Novel human hepatic organoid model enables testing of drug-induced liver fibrosis in vitro [J]. Biomaterials, 2016, 78: 1-10.
[89] Ouchi R, Togo S, Kimura M, et al. Modeling steatohepatitis in humans with pluripotent stem cell-derived organoids [J]. Cell Metab, 2019, 30(2): 374-384.
[90] Mederacke I, Hsu CC, Troeger JS, et al. Genetic labeling does not detect epithelial-to-mesenchymal transition of cholangiocytes in liver fibrosis in mice [J]. Gastroenterology, 2013, 139: 987-998.
[91] Sun Lulu, Wang Yuqing, Cen Jin, et al. Modelling liver cancer initiation with organoids derived from directly reprogrammed human hepatocytes [J]. Nature Cell Biology, 2019, 21(8): 1015-1026.
[92] Buzzelli JN, Ouaret D, Brown G, et al. Colorectal cancer liver metastases organoids retain characteristics of original tumor and acquire chemotherapy resistance [J]. Stem Cell Research, 2018, 27: 109-120.
[93] Cao Wanlu, Liu Jiaye, Wang Lin, et al. Modeling liver cancer and therapy responsiveness using organoids derived from primary mouse liver tumors [J]. Carcinogenesis, 2018, 40(1): 145-154.
[94] Kaplowitz N. Idiosyncratic drug hepatotoxicity [J]. Nat Rev Drug Discov, 2005, 4(6): 489-499.
[95] Sgodda M, Dai Z, Zweigerdt R, et al. A scalable approach for the generation of human pluripotent stem cell-derived hepatic organoids with sensitive hepatotoxicity features [J]. Stem Cells and Development, 2017, 26(20): 1490-1504.
[96] Bell CC, Hendriks DFG, Moro SML, et al. Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease [J]. Scientific Reports, 2016, 6(1): 25187.
[97] Chakraborty M, Fullerton AM, Semple K, et al. Drug-induced allergic hepatitis develops in mice when myeloid-derived suppressor cells are depleted prior to halothane treatment [J]. Hepatology, 2015, 62: 546-557.
[98] Metushi IG, Hayes MA, Uetrecht J. Treatment of PD-1-/-mice with amodiaquine and anti-CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients [J]. Hepatology, 2015, 61(4): 1332-1342.
[99] Kostadinova R, Boess F, Applegate D, et al. A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity [J]. Toxicol Appl Pharmacol, 2013, 268(1): 1-16.
[100] Minchinton AI, Tannock IF. Drug penetration in solid tumours [J]. Nat Rev Cancer, 2006, 6(8): 583-592.
[101] Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: A major contributor to minimal residual disease [J]. Nat Rev Cancer, 2009, 9(9): 665-674.
[102] Broutier L, Andersson-Rolf A, Hindley CJ, et al. Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation [J]. Nat Protoc, 2016, 11: 1724-1743.
[103] Lindemans CA, Calafiore M, Mertelsmann AM, et al. Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration [J]. Nature, 2015, 528(7583): 560-564.
[104] Hou Qihang, Ye Lulu, Liu Haofei, et al. Lactobacillus accelerates ISCs regeneration to protect the integrity of intestinal mucosa through activation of STAT3 signaling pathway induced by LPLs secretion of IL-22 [J]. Cell Death Differ, 2018, 25(9): 1657-1670. |
|
|
|
